CN110133298A - 疾病样品分析装置、分析系统及分析方法 - Google Patents

疾病样品分析装置、分析系统及分析方法 Download PDF

Info

Publication number
CN110133298A
CN110133298A CN201910585649.7A CN201910585649A CN110133298A CN 110133298 A CN110133298 A CN 110133298A CN 201910585649 A CN201910585649 A CN 201910585649A CN 110133298 A CN110133298 A CN 110133298A
Authority
CN
China
Prior art keywords
amino acid
disease
concentration
mouse
acid stereoisomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910585649.7A
Other languages
English (en)
Chinese (zh)
Inventor
浜濑健司
东條洋介
三田真史
水本智惠子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirror Co.,Ltd.
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Publication of CN110133298A publication Critical patent/CN110133298A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/89—Inverse chromatography
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8818—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8877—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201910585649.7A 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法 Pending CN110133298A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012061305 2012-03-18
JP2012-061305 2012-03-18
CN201380019921.6A CN104246497B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380019921.6A Division CN104246497B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法

Publications (1)

Publication Number Publication Date
CN110133298A true CN110133298A (zh) 2019-08-16

Family

ID=49222264

Family Applications (11)

Application Number Title Priority Date Filing Date
CN201910586450.6A Expired - Fee Related CN110133300B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910586159.9A Pending CN110133299A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201710913596.8A Expired - Fee Related CN107449923B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910585649.7A Pending CN110133298A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910591882.6A Active CN110161256B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910585588.4A Pending CN110133297A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910591893.4A Active CN110133301B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN202210524153.0A Pending CN114966050A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910585530.XA Active CN110133296B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201380019921.6A Expired - Fee Related CN104246497B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910585495.1A Pending CN110133295A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CN201910586450.6A Expired - Fee Related CN110133300B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910586159.9A Pending CN110133299A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201710913596.8A Expired - Fee Related CN107449923B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法

Family Applications After (7)

Application Number Title Priority Date Filing Date
CN201910591882.6A Active CN110161256B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910585588.4A Pending CN110133297A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910591893.4A Active CN110133301B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN202210524153.0A Pending CN114966050A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910585530.XA Active CN110133296B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201380019921.6A Expired - Fee Related CN104246497B (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法
CN201910585495.1A Pending CN110133295A (zh) 2012-03-18 2013-03-18 疾病样品分析装置、分析系统及分析方法

Country Status (7)

Country Link
US (2) US20150079623A1 (enExample)
EP (3) EP2829877B1 (enExample)
JP (3) JP6037388B2 (enExample)
CN (11) CN110133300B (enExample)
IN (1) IN2014MN02060A (enExample)
TW (2) TWI664425B (enExample)
WO (1) WO2013140785A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105793712B (zh) * 2013-12-11 2018-01-05 株式会社资生堂 肾衰竭的早期诊断标志物
CN107683414A (zh) * 2015-06-10 2018-02-09 国立大学法人金泽大学 肾病的病态生物标志物
CN108587991B (zh) * 2015-10-10 2021-03-05 中国科学院南海海洋研究所 一种高产环肽类化合物的菌株
EP3460477A4 (en) * 2016-05-17 2020-01-08 Osaka University METHOD AND SYSTEM FOR PROGNOSING FORECAST OF A KIDNEY DISEASE
SG11201810254UA (en) * 2016-05-17 2018-12-28 Univ Osaka Blood sample analysis method and system, for determining diabetes
WO2018092818A1 (ja) 2016-11-15 2018-05-24 株式会社資生堂 多次元クロマトグラフィー分析方法及び分析システム
WO2018159833A1 (ja) * 2017-03-02 2018-09-07 株式会社ニコン 細胞の判別方法、がんの検査方法、計測装置、がんの検査装置および検査プログラム
WO2018159841A1 (ja) 2017-03-03 2018-09-07 株式会社資生堂 新規化合物、当該新規化合物を含む蛍光誘導体化用試薬、並びに当該新規化合物を用いたアミノ酸の光学異性体を光学分割する方法及び蛍光誘導体化されたアミノ酸
US12220394B2 (en) 2018-06-07 2025-02-11 National University Corporation Kanazawa University Pharmaceutical composition for prevention or treatment of kidney damage
JP7366428B2 (ja) * 2018-08-27 2023-10-23 Kagami株式会社 乾癬を判定するための皮膚試料の分析方法及びシステム
WO2020080484A1 (ja) 2018-10-17 2020-04-23 株式会社 資生堂 糸球体濾過能力の決定方法
JP7733909B2 (ja) * 2019-03-22 2025-09-04 Kagami株式会社 腎病態の評価を補助する方法、腎病態の評価システム及び腎病態の評価プログラム
EP3943948B1 (en) 2019-03-22 2025-07-09 Kagami Inc. Method for assisting evaluation of condition of kidneys, system for evaluating condition of kidneys, and program for evaluating condition of kidneys
JP7434678B2 (ja) * 2019-05-20 2024-02-21 花王株式会社 認知症又はそのリスクの検査方法
EP4083628A4 (en) 2019-12-27 2024-02-21 Kagami Inc. METHOD AND SYSTEM FOR ESTIMATING RENAL FUNCTION
CN112180007B (zh) * 2020-09-16 2023-08-18 上海市皮肤病医院 基于代谢组学的泛发性脓疱型银屑病诊断标志物及其应用
CN111899883B (zh) * 2020-09-29 2020-12-15 平安科技（深圳）有限公司 少样本或零样本的疾病预测设备、方法、装置及存储介质
JP7600016B2 (ja) * 2021-03-30 2024-12-16 花王株式会社 高次脳機能の測定方法
WO2023033178A1 (ja) * 2021-09-03 2023-03-09 Kagami株式会社 癌についての情報を提供する方法、癌についての情報を提供するシステム及び癌を治療する方法

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4290893A (en) * 1979-05-08 1981-09-22 Yeda Research & Development Co. Ltd. Separation of amino acids by liquid chromatography using chiral eluants
CN1051914A (zh) * 1989-11-22 1991-06-05 默里尔多药物公司 肽类
CA2238993A1 (en) * 1995-12-15 1997-06-26 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with lhrh antagonists
CN1263535A (zh) * 1997-06-02 2000-08-16 塞拉麦克思实验室公司 Lh－rh肽类似物、其用途及含有它们的药物组合物
US20020006399A1 (en) * 1999-12-27 2002-01-17 Kenneth Weisman Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
WO2004087190A1 (en) * 2003-04-02 2004-10-14 Genix Therapeutics Inc. Method for the treatment of prostate cancer
EP1577323A1 (en) * 2002-12-26 2005-09-21 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
CN1761484A (zh) * 2003-02-21 2006-04-19 梅德维特科学股份有限公司 诊断和治疗的方法
CN101262872A (zh) * 2005-09-16 2008-09-10 株式会社资生堂 新型血管内皮生长因子表达抑制剂
WO2009143489A2 (en) * 2008-05-22 2009-11-26 Archer Pharmaceuticals, Inc. Modulation of angiogenesis by a-beta peptide fragments
US20100112089A1 (en) * 2008-05-14 2010-05-06 Takeda Pharmaceutical Company Limited Peptide compound and use thereof
CN102079771A (zh) * 2010-12-10 2011-06-01 郑州大学 具有抗肿瘤活性的雌甾氨基酸酯化合物及其合成方法
CN102124103A (zh) * 2008-08-26 2011-07-13 国立大学法人九州大学 利用了Dao1-/-小鼠的D-氨基酸相关疾病的评价筛选方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374651A (en) * 1991-09-27 1994-12-20 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives
AU5360796A (en) * 1995-03-09 1996-10-02 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
JPH0975078A (ja) * 1995-09-13 1997-03-25 Ikeda Shokken Kk 耐熱性ｄ−アミノ酸オキシダーゼ、その製造法および微生物
HK1039904A1 (zh) * 1998-06-11 2002-05-17 福克斯契思癌症中心 评估糖尿病患者发生糖尿病相关病理情况的危险度的方法
EP1183521B1 (en) * 1999-05-14 2014-03-19 Brandeis University Aptamer-based detection
US7223558B2 (en) * 2001-07-11 2007-05-29 Bristol-Myers Squibb Company Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
FR2828693B1 (fr) * 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
WO2003072059A2 (en) * 2002-02-27 2003-09-04 Wake Forest University Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
FR2838444B1 (fr) * 2002-04-10 2016-01-01 Neovacs Nouveaux peptides et leur application en therapeutique
US20070298041A1 (en) * 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
EP1542017A4 (en) * 2002-07-04 2007-07-11 Mitsubishi Pharma Corp METHOD FOR EXAMINING AND DIAGNOSING THE INTEGRATION ERROR SYNDROME
GB0219776D0 (en) * 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma
GB0223424D0 (en) * 2002-10-09 2002-11-13 Imp College Innovations Ltd Disease-associated gene
CA2508136A1 (en) * 2002-12-09 2004-06-24 Ajinomoto Co., Inc. Apparatus and method for processing information concerning biological condition, system, program and recording medium for managing information concerning biological condition
EP1601948A2 (en) * 2003-03-10 2005-12-07 Sionex Corporation Systems for differential ion mobility analysis
JP4291628B2 (ja) 2003-06-12 2009-07-08 株式会社資生堂 液体クロマトグラフ装置及び試料に含まれる光学異性体の分析方法
CN1557823A (zh) * 2004-02-12 2004-12-29 窦德献 L-或d-氨基酸合铂配位体、制备方法及其用途
US7901881B2 (en) * 2004-04-09 2011-03-08 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic tool for diagnosing benign versus malignant thyroid lesions
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
GB0417887D0 (en) * 2004-08-11 2004-09-15 Ares Trading Sa Protein
ES2594885T3 (es) * 2005-03-18 2016-12-23 Shiseido Company, Limited Método para evaluar una enfermedad de la piel utilizando un antígeno relacionado con el carcinoma de células escamosas como medida
CN101189243A (zh) * 2005-04-06 2008-05-28 阿斯利康(瑞典)有限公司 取代的杂环及其作为chk1、pdk1和pak抑制剂的应用
AU2007224240B2 (en) * 2006-03-02 2013-07-25 Revvity Health Sciences, Inc. Methods for distinguishing isomers using mass spectrometry
US20070258899A1 (en) * 2006-03-31 2007-11-08 Karyon-Ctt Ltd Diagnostic and therapeutic agents
JP5005955B2 (ja) * 2006-05-24 2012-08-22 田辺三菱製薬株式会社 被験物質の脂質代謝異常症誘発可能性を予測する方法
ES2427924T3 (es) * 2006-06-30 2013-11-04 Merck Sharp & Dohme Corp. Biomarcador IGFBP2
EP1900742A1 (en) * 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
BRPI0716190A2 (pt) * 2006-09-06 2013-11-12 Aeterna Zentaris Gmbh Conjugados de disorazóis e seus derivados com móleculas de ligação celular, derivados de disorazol, processos para fabricação e uso dos mesmos
US20090075284A1 (en) * 2006-09-19 2009-03-19 The Regents Of The University Of Michigan Metabolomic profiling of prostate cancer
KR20090111322A (ko) * 2007-01-18 2009-10-26 세프라코 아이엔시. 디 아미노산 옥시다제의 억제제
JP2010518812A (ja) * 2007-02-12 2010-06-03 アンスロジェネシス コーポレーション 接着性胎盤幹細胞由来の肝細胞および軟骨細胞、ならびにｃｄ３４＋、ｃｄ４５−胎盤幹細胞の濃縮細胞集団
US8034780B2 (en) * 2007-07-16 2011-10-11 Mcphail Kerry Leigh Isolation, purification, and structure elucidation of the antiproliferative compound coibamide A
WO2009091023A1 (ja) * 2008-01-17 2009-07-23 Toray Industries, Inc. 腎癌の診断又は検出のための組成物及び方法
JP2009184981A (ja) * 2008-02-07 2009-08-20 Shiseido Co Ltd 抗ｄ−アミノ酸モノクローナル抗体及び、抗ｄ−アミノ酸モノクローナル抗体を用いたｄ−アミノ酸の免疫学的分析方法
WO2010005982A2 (en) * 2008-07-07 2010-01-14 The General Hospital Corporation Multiplexed biomarkers of insulin resistance
JP2010038796A (ja) * 2008-08-06 2010-02-18 Human Metabolome Technologies Inc 疾患マーカー、および、疾患マーカーの測定方法
US8722343B2 (en) * 2008-11-21 2014-05-13 Carla Perego Methods and compositions for the diagnosis and treatment of diabetes
ES2799327T3 (es) * 2009-05-05 2020-12-16 Infandx Ag Método para diagnosticar asfixia
CN101619092B (zh) * 2009-08-06 2012-08-15 中国人民解放军第三军医大学第二附属医院 肿瘤抗原trag-3模拟表位肽及其应用
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
JP2011247869A (ja) * 2010-04-27 2011-12-08 Kobe Univ メタボローム解析手法を用いた特定疾患の検査方法

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4290893A (en) * 1979-05-08 1981-09-22 Yeda Research & Development Co. Ltd. Separation of amino acids by liquid chromatography using chiral eluants
CN1051914A (zh) * 1989-11-22 1991-06-05 默里尔多药物公司 肽类
CA2238993A1 (en) * 1995-12-15 1997-06-26 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with lhrh antagonists
CN1263535A (zh) * 1997-06-02 2000-08-16 塞拉麦克思实验室公司 Lh－rh肽类似物、其用途及含有它们的药物组合物
US20020006399A1 (en) * 1999-12-27 2002-01-17 Kenneth Weisman Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
EP1577323A1 (en) * 2002-12-26 2005-09-21 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
CN1761484A (zh) * 2003-02-21 2006-04-19 梅德维特科学股份有限公司 诊断和治疗的方法
WO2004087190A1 (en) * 2003-04-02 2004-10-14 Genix Therapeutics Inc. Method for the treatment of prostate cancer
CN101262872A (zh) * 2005-09-16 2008-09-10 株式会社资生堂 新型血管内皮生长因子表达抑制剂
US20100112089A1 (en) * 2008-05-14 2010-05-06 Takeda Pharmaceutical Company Limited Peptide compound and use thereof
WO2009143489A2 (en) * 2008-05-22 2009-11-26 Archer Pharmaceuticals, Inc. Modulation of angiogenesis by a-beta peptide fragments
CN102124103A (zh) * 2008-08-26 2011-07-13 国立大学法人九州大学 利用了Dao1-/-小鼠的D-氨基酸相关疾病的评价筛选方法
CN102079771A (zh) * 2010-12-10 2011-06-01 郑州大学 具有抗肿瘤活性的雌甾氨基酸酯化合物及其合成方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HANS BRUCKNER 等: ""Gas chromatographic characterization of free D-amino acids in the blood serum of patients with renal disorders and of healthy volunteers"", 《JOURNAL OF CHROMATOGRAPHY》 *
KENJI HAMASE 等: ""d-Amino acids in mammals and their diagnostic value"", 《JOURNAL OF CHROMATOGRAPHY B》 *
TAKESHI FUKUSHIMA 等: ""Determination of D-Amino Acids in Serum from Patients with Renal Dysfunction"", 《BIOLOGICAL & PHARMACEUTICAL BULLETIN》 *
VERMA, MUKESH 等: ""Proteomic Approaches within the NCI Early Detection Research Network for the Discovery and Identification of Cancer Biomarkers"", 《ANNALS NEW YORK ACADEMY OF SCIENCES》 *
YOHEI MIYAGI 等: ""Plasma Free Amino Acid Profiling of Five Types of Cancer Patients and Its Application for Early Detection"", 《PLOS ONE》 *
李琼瑶 等: ""D-天冬酰胺和D-高丝氨酸的制备研究"", 《氨基酸和生物资源 》 *
邹永浩 等: ""脆性组氨酸三体和血管内皮生长因子在前列腺癌组织中的表达"", 《现代泌尿外科杂志》 *

Also Published As

Publication number Publication date
CN110133295A (zh) 2019-08-16
US20150079623A1 (en) 2015-03-19
CN110133297A (zh) 2019-08-16
CN107449923A (zh) 2017-12-08
JP2017223711A (ja) 2017-12-21
CN110133299A (zh) 2019-08-16
CN110161256B (zh) 2022-03-25
CN114966050A (zh) 2022-08-30
WO2013140785A1 (ja) 2013-09-26
EP3795997B1 (en) 2022-08-24
CN104246497B (zh) 2017-10-13
EP2829877A1 (en) 2015-01-28
JP6214016B2 (ja) 2017-10-18
EP2829877B1 (en) 2020-01-22
CN110133301A (zh) 2019-08-16
CN110133296B (zh) 2022-03-25
US20190025320A1 (en) 2019-01-24
CN110161256A (zh) 2019-08-23
TW201736851A (zh) 2017-10-16
TW201344194A (zh) 2013-11-01
TWI615614B (zh) 2018-02-21
IN2014MN02060A (enExample) 2015-08-21
JP2017015741A (ja) 2017-01-19
EP2829877A4 (en) 2015-12-09
CN110133296A (zh) 2019-08-16
CN104246497A (zh) 2014-12-24
CN107449923B (zh) 2020-07-24
CN110133300A (zh) 2019-08-16
EP3663758A1 (en) 2020-06-10
TWI664425B (zh) 2019-07-01
JP6037388B2 (ja) 2016-12-07
CN110133300B (zh) 2022-02-25
CN110133301B (zh) 2022-03-22
JP2013224929A (ja) 2013-10-31
JP6391787B2 (ja) 2018-09-19
EP3795997A1 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
CN110133298A (zh) 疾病样品分析装置、分析系统及分析方法
JP2013224929A5 (enExample)
US20190339281A1 (en) Marker for early diagnosis of kidney failure
Hagiya et al. Expression levels of PEPT1 and ABCG2 play key roles in 5-aminolevulinic acid (ALA)-induced tumor-specific protoporphyrin IX (PpIX) accumulation in bladder cancer
Lin Thyroglobulin and human thyroid cancer
Zhao et al. Mitochondrial translocator protein (TSPO) function is not essential for heme biosynthesis
CN109154621B (zh) 肾脏病的预后预测方法及系统
CN109154619A (zh) 用于判定糖尿病的血液试样的分析方法及系统
St-Pierre et al. Association between nesfatin-1 levels and metabolic improvements in severely obese patients who underwent biliopancreatic derivation with duodenal switch
WO2020196436A1 (ja) 腎病態の評価を補助する方法、腎病態の評価システム及び腎病態の評価プログラム
US10753924B2 (en) Method for selecting patients responsive for cancer treatments
Markuszewski et al. Session 16. Clinical Metabolomics
HK40002815A (en) Blood sample analysis method and system, for determining diabetes
DZAPARIDZE Quantification and evaluation of the diagnostic significance of adenocarcinoma-associated microenvironmental changes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200713

Address after: Osaka Japan

Applicant after: Mirror Co.,Ltd.

Address before: Tokyo, Japan

Applicant before: SHISEIDO Co.,Ltd.

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190816

WD01 Invention patent application deemed withdrawn after publication